Non-invasive monitoring Target transplant centers and hospitals seeking non-invasive, highly sensitive diagnostic tests for organ transplant monitoring. Position TAIDiagnostics as a solution that reduces need for invasive biopsy procedures and enables earlier detection of organ rejection.

Early-stage growth Leverage the company’s Series A funding and recent partnerships to engage early-stage customers and strategic collaborators. Highlight growth trajectory and investor confidence to build credibility with potential clients and distributors.

Strategic partnerships Develop co‑development and distribution agreements with biopharma and device companies already active in transplant care, leveraging past partnerships with United Therapeutics and Unither Bioélectronique to expand market reach.

Small but focused Emphasize the lean team and cross‑functional capabilities to position the company as a nimble partner for hospitals and academic medical centers seeking tailored, faster deployment of new diagnostic tools.

Market positioning Target comparisons with larger gene and genomic players by offering a focused, transplant-specific monitoring solution with clear clinical and economic value, and pursue pilot programs at transplant centers to demonstrate ROI and clinical utility.